Loperamide-induced hypopituitarism
- PMID: 27681351
- PMCID: PMC5051368
- DOI: 10.1136/bcr-2016-216384
Loperamide-induced hypopituitarism
Abstract
Loperamide is the most commonly used antidiarrhoeal medication in the UK. We report a serious and hitherto undocumented adverse effect of chronic use in a 45-year-old man with inflammatory bowel disease. He presented to the endocrine clinic with fatigue and low libido; biochemical assessment revealed hypogonadism and adrenal insufficiency without any elevated adrenocorticotropic hormone. When symptoms allowed, loperamide was reduced and a short synacthen test (SST) showed a 'clear pass' with a normal peak cortisol of 833 nmol/L. Later, worsening diarrhoea necessitated an escalation in loperamide use again. While taking a daily dose of 15-20 mg (recommended daily maximum 16 mg) reassessment revealed a fall in peak cortisol on SST to 483 nmol/L, a subnormal response. Clinicians should exercise caution when relying on loperamide to manage their patients' chronic diarrhoea and remain mindful of the possibility of drug-induced life-threatening adrenal insufficiency.
2016 BMJ Publishing Group Ltd.
References
-
- Health & Social Care Information Centre Prescription Cost Analysis, England 2014. (publication date: April 08, 2015). http://www.hscic.gov.uk/catalogue/PUB17274 (accessed 24 Jun 2015).
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources